ERCC1 and urinary bladder carcinoma: Notably, a previous systematic review comprehensively summarized the applications of classical biomarkers such as CYFRA 21.1, ERCC1, p53, FGFR3, and TATI in bladder cancer diagnosis and prognosis and confirmed their significant advantages and clinical potential in early diagnosis, recurrence monitoring, and individualized treatment (61).